SCHEMBL2404852

SCHEMBL2404852

[CH2]Cc1ccc(OCCCC)cc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.53
NR5A1 Q13285 1/20 0.52
CYP2D6 P10635 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
PDE4A P27815 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HIF1A Q16665 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
TSHR P16473 1/20 0.51
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677003 0.96 NR5A1 (0.58) LTA4HNR5A1TSHR
SCHEMBL2923822 0.94 NR5A1 (0.61) LTA4HNR5A1SMN1; SMN2TSHRCYP3A4
SCHEMBL677822 0.94 NR5A1 (0.61) LTA4HNR5A1SMN1; SMN2TSHRCYP3A4
SCHEMBL11864805 0.94 NR5A1 (0.61) LTA4HNR5A1SMN1; SMN2TSHRCYP3A4
SCHEMBL10568354 0.94 NR5A1 (0.61) LTA4HNR5A1SMN1; SMN2TSHRCYP3A4
SCHEMBL676996 0.94 NR5A1 (0.61) LTA4HNR5A1SMN1; SMN2TSHRCYP3A4
SCHEMBL3195193 0.91 L3MBTL1 (0.53) LTA4HKDM4ECYP1A2SMN1; SMN2
SCHEMBL3028156 0.83 LMNA (0.53) LTA4HNR5A1CYP2D6KDM4ECYP1A2
SCHEMBL26850 0.83 LTA4H (0.70) LTA4HNR5A1CYP2D6CYP1A2SMN1; SMN2
SCHEMBL5187268 0.83 HRH3 (0.40) LTA4HSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115867534-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-28 CN disclosed
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 US disclosed
US-8025936-B2 Optical compensation film, polarizing plate and liquid crystal display device FUJIFILM CORPORATION (JP) 2011-09-27 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
US-20090091690-A1 Optical Compensation Film, Polarizing Plate and Liquid Crystal Display Device FUJIFILM CORPORATION (JP) 2009-04-09 US disclosed
US-7417104-B2 Porous film-forming composition, patterning process, and porous sacrificial film SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-08-26 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 EP disclosed
EP-0726486-B1 Optical compensatory sheet FUJI PHOTO FILM CO LTD (JP) 2005-04-20 EP disclosed
EP-1180765-B1 Optical recording medium and porphycene compound MITSUI CHEMICALS INC (JP) 2005-04-06 EP disclosed
EP-1180765-A1 Optical recording medium and porphycene compound Mitsui Chemicals, Inc. (JP) 2002-02-20 EP disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed
US-5747121-A POLYMER OF ORIENTATION LAYER IS CHEMICALLY BONDED TO THE LIQUID CRYSTALLINE COMPOUND OF THE OPTICALLY ANISOTROPIC LAYER VIA THE INTERFACE OF THESE LAYERS FUJI PHOTO FILM CO., LTD. (JP) 1998-05-05 US disclosed
EP-0726486-A2 Optical compensatory sheet FUJI PHOTO FILM CO., LTD. (JP) 1996-08-14 EP disclosed
US-5518783-A TRANSPARENT SUPPORT HAVING OPTIC AXIS INCLINED AT SPECIFIED ANGLE TO NORMAL, OPTICALLY ANISOTROPIC LAYER FORMED FROM DISCOTIC COMPOUND AND COMPATIBLE COMPOUND WHICH LOWERS TRANSITION TEMPERATURE FUJI PHOTO FILM CO., LTD. (JP) 1996-05-21 US disclosed
EP-0676652-A2 Optical compensatory sheet and liquid crystal display FUJI PHOTO FILM CO., LTD. (JP) 1995-10-11 EP disclosed
US-4249027-A Process for the preparation of 5-substituted resorcinols and related intermediates CIBA-GEIGY CORPORATION (US) 1981-02-03 US disclosed
US-4020098-A Process for the preparation of 5-substituted resorcinols and related intermediates CIBA-GEIGY CORPORATION (US) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 LTA4H 221/4885NR5A1 4356/4885CYP2D6 4781/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 LTA4H 862/4885NR5A1 4121/4885CYP2D6 4722/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 LTA4H 304/4885NR5A1 4047/4885CYP2D6 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.